In:
Journal of Labelled Compounds and Radiopharmaceuticals, Wiley, Vol. 58, No. 7 ( 2015-06-15), p. 308-312
Kurzfassung:
Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo . In particular, deuterated compound SKLB‐C2202 had significantly improved pharmacokinetic properties compared with nintedanib. These efforts lay the foundation for further investigating the druggability of SKLB‐C2202.
Materialart:
Online-Ressource
ISSN:
0362-4803
,
1099-1344
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2015
ZDB Id:
1491841-9
SSG:
15,3
Permalink